Re: Additional Exempt Distribution- 2023-03-31

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KayakerBC

Rank: Treasurer [?]

Points: 1691 [?]

Votes: 23 Score: 2.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Exempt Distribution- 2023-03-31

in response to

Re: Additional Exempt Distribution- 2023-03-31

Buckeyes

posted on Apr 12, 2023 09:49AM

It's only that one Hong Kong investor who has been accepting Nov 2023 warrants. This, from the Apr 6 2023 "Interim financial statements/report" tells me everything I need to know about timing......

"....In connection with the additional CAD$1.7 million advanced by a relative of the Chief Executive Officer / Chairman of the Company, the Company issued a total of 1,350,000 warrants. Each warrant is exercisable at a price of $0.75 per underlying common share for a period of five years from the respective grant dates...."